Skip to main content Accessibility help
×
×
Home

Continuous Dopaminergic Stimulation in Parkinson's Disease

  • J.A. Obeso (a1), M.R. Luquin (a1), J. Vaamonde (a1), F. Grandas (a1) and J.M. Martinez Lage (a1)...
Abstract:

Complex motor fluctuations and dyskinesias (“on-off” phenomenon) in Parkinson's disease can be corrected by parenteral administration of levodopa, levodopa-methyl-ester, lisuride and apomorphine. Levodopa and levodopa-methyl-ester may only be administered intravenously because of their low solubility. Lisuride and apomorphine are readily absorbed after subcutaneous administration. Repeated or continuous intravenous infusions of levodopa have been given for a few days, using a wearable “jacket-like” pump, with good results. So far, lisuride is the only dopamine agonist used for chronic treatment by continuous infusion. The “on-off” effect is adequately controlled in most patients by subcutaneous lisuride administration (plus oral levodopa). However, adverse effects, particularly psychiatric complications, constitute a major limiting factor for routine applications of this form of treatment. Subcutaneous apomorphine infusion is unlikely to become a standard therapeutic procedure in Parkinson's disease, but it is a very valuable research method to gain further insight into the pathophysiology of motor fluctuations in Parkinson's disease.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Continuous Dopaminergic Stimulation in Parkinson's Disease
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Continuous Dopaminergic Stimulation in Parkinson's Disease
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Continuous Dopaminergic Stimulation in Parkinson's Disease
      Available formats
      ×
Copyright
Corresponding author
Clinica Universitaria, Apartado 19, 31080 Pamploma, Spain
References
Hide All
1.Marsden, CD, Parkes, JD. “On-off” effects in patients with Parkinson’s disease in chronic levodopa therapy. Lancet 1976; 1: 292296.
2.Lewitt, PA, Chase, TN. “On-off” effects; the new challenge in parkinsonism. Trends Neurosci 1983; 6: 14.
3.Fahn, S. Fluctuations of disability in Parkinson’s disease: Patho-physiology. In: Movement Disorders, ed. Marsden, CD and Fahn, S. Butterworth, London 1982; 123145.
4.Marsden, CD, Parkes, JD, Quinn, N. Fluctuations of disability in Parkinson’s disease: Pathophysiological aspects. In: Movement Disorders. Marsden, CD and Fahn, S, eds. Butterworth, London 1982; 96122.
5.Fahn, S. Episodic failure of absorption of L-dopa: A factor in the control of clinical fluctuations in the treatment of parkinsonism. Neurology 1977; 27 (suppl 2): 390.
6.Melamed, E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch of Neurology 1986; 43: 402405.
7.Schwab, RS, Amador, LV, Lettvin, JY. Apomorphine in Parkinson’s disease. Trans Amer Neurol Assoc 1951; 76: 25122513.
8.Nutt, JG, Fellman, JH. Pharmacokinetics of levodopa. Clin Neuro-pharm 1984; 7: 3550.
9.Gervas, JJ, Muradas, V, Bazan, E, et al. Effects of 3-OM-dopa on monamine metabolism in rat brain. Neurology (Cleveland) 1983; 33: 278282.
10.Reches, A, Nuelke, LR, Fahn, S. 3-0-Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology (NY) 1983; 32: 887888.
11.Sthal, S. Applications of new drug delivery technologies to Parkinson’s disease and dopaminergic agents. J Neural Trans (in press).
12.Obeso, JA, Sthal, S. New routes of administration for antiparkinsonian therapy. “Drugs for the treatment of Parkinson’s disease”. Calne, DB, Springer-Verlag, Berlin (in press).
13.Shoulson, I, Glaubiger, GA, Chase, TN. On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975: 25: 11441148.
14.Rosin, AJ, Devereux, D, Calne, DB. Parkinsonism with “on-off” phenomena-intravenous treatment with levodopa after major abdominal surgery. Arch Neurol 1979; 36: 3234.
15.Quinn, NP, Parkes, JD, Marsden, CD. Control of “on-off” phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 11311136.
16.Hardie, RJ, Lees, AJ, Stern, GM. On-off fluctuations in Parkinson’s disease: A clinical and neuropharmacological study. Brain 1984; 107: 487506.
17.Nutt, JG, Woodward, WR, Hammerstad, JP, et al. The “on-off” phenomenon in Parkinson’s disease. New Eng J Med 1984; 310: 483488.
18.Marion, MH, Stocchi, F, Quinn, NP, et al. Repeated levodopa infusions in fluctuating Parkinson’s disease: Clinical and pharmacokinetic data. Clin Neuropharm 1986; 9: 165181.
19.Chase, TN, Mouradian, MM, Fabbrini, G, et al. Pathogenetic studies of motor fluctuations in Parkinson’s disease. J Neurol Trans (in press).
20.Luquin, MR, Obeso, JA, Martinez Lage, JM, et al. Levodopa and 3-0-Methyldopa plasma levels in Parkinson’s disease: Patients with clinical fluctuations versus smooth responders. Neurology 1986; 36 (supp 1): 244.
21.Cooper, DR, Marrel, C, Testa, B, et al. L-Dopa Methyl Ester: A candidate for chronic systemic deli very of L-Dopa in Parkinson’s disease. Clin Neuropharm 1984; 7: 8898.
22.Obeso, JA, Martinez Lage, JM, Luqwuin, MR. Lisuride infusion for Parkinson’s disease. Ann Neurol 1983; 14: 134.
23.Obeso, JA, Luquin, MR, Martinez Lage, JM. Intravenous lisuride corrects motor oscillations in Parkinson’s disease. Ann Neurol 1986a; 19: 3135.
24.Luquin, MR, Obeso, JA, Martinez Lage, JM, et al. Parenteral administration of lisuride in Parkinson’s disease. Adv Neurol 1987: 45.
25.Obeso, JA, Luquin, MR, Martinez Lage, JM. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1986b; 1: 467470.
26.Obeso, JA, Luquin, MR, Vaamonde, J, et al. Continuous subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease. J Neural Trans (in press).
27.Critchley, P, Grandas, F, Quinn, N, et al. Continuous subcutaneous lisuride infusions in Parkinson’s disease. J Neural Trans (in press).
28.Ruggieri, S, Stocchi, F, Agnoli, A. Lisuride infusion pump for Parkinson’s disease. Lancet 1986; 11: 348349.
29.Vaamonde, J, Obeso, JA, Luquin, R. Increased levodopa consumption reduces motor response to apomorphine in Parkinson’s disease. Neurology 1987; (suppl 1): 37.
30.Cotzias, GC, Mena, I, Papavasilious, PS. Overview of present treatment of parkinsonism with levodopa. Adv Neurol 1973; 2: 265277.
31.Winkler, JD, Weiss, B. Reversal of supersensitivity apomorphine induced rotational behaviour in mice by continuous exposure to apomorphine. J Phar Exp Therap 1986; 238: 242247.
32.Stoessl, AJ, Mak, E, Calne, DB. (+)-4-propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism. Lancet 1985; 2: 13301331.
33.Grandas Perez, F, Jenner, J, Nomoto, M, et al. (+)-4-propyl-9-hydroxynaphthoxazine in Parkinson’s disease. Lancet 1986; 1: 906.
34.Coleman, RJ, Grandas Perez, F, Quinn, N, et al. 4-propyl-9-hydroxy-naphthoxazine in Parkinson’s disease and MPTP models (in press).
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Canadian Journal of Neurological Sciences
  • ISSN: 0317-1671
  • EISSN: 2057-0155
  • URL: /core/journals/canadian-journal-of-neurological-sciences
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed